The Europe Nifedipine market size is expected to reach a valuation of USD 648.08 million by 2030, driving at a CAGR of 8.5 % during the forecast period (2022–2030).
Nifedipine is a calcium channel blocker, which means it prevents calcium from passing through the arteries walls. Nifedipine is used to cure high blood pressure, arrhythmias, and angina. Other therapeutic applications include ryanoids syndrome, cephalalgia, and other similar conditions. The market is being driven by a growth in the senior population, healthcare spending, the incidence of chronic conditions such heart failure, arrhythmias, and hypertension, and healthcare awareness. On the other hand, market expansion is hampered by government laws and unfavourable pharmacological consequences like hypotension, stomach ulcers, and congestive heart failure. New development prospects are anticipated to emerge from R&D activities. HBP problems are treated with dihydropyridine calcium channel blockers such nitrendipine and nisoldipine. Premature labour has been more common in recent years, resulting in an increase in demand for the drugs described above. Premature labour is treated with tocolytics, which work by inhibiting muscle contractions. Similarly, nifedipine protects preemies from developing health problems as a result of their premature birth. The global nifedipine market was worth USD 856.66 million in 2020, and is expected to increase to USD 1,792.36 million by 2029, showing an annual growth rate of 8.49% (CAGR).
The new WHO European Regional Obesity Report 2022, released on 3 May by the WHO Regional Office for Europe, shows that overweight and obesity rates have reached epidemic proportions across the Region and are still rising, with none of the Region's 53 Member States on track to meet the WHO Global Noncommunicable Disease (NCD) target of halting obesity rise by 2025 and owing to this, more diseases are becoming prevalent rising the demand for the nifedipine market in the region.
The two varieties of nifedipine pills are nifedipine controlled-release tablets and nifedipine extended-action tablets. In 2021, the controlled-release pills of nifedipine had the most market share. Rising rates of hypertension and heart failure, the use of cutting-edge technology in pharmaceutical research, more funding from the government and international organisations, and increased public awareness about the importance of preventative treatment can all be attributed to this significant increase.
Based on the application, the section is divided into primary pulmonary hypertension, heart failure, Raynaud's disease, cephalalgia, and others. Primary pulmonary hypertension was the most common cause of pulmonary hypertension in 2021. Obesity, poor dietary habits, excessive junk food consumption, a lack of exercise, an increase in the younger generation's smoking and alcohol consumption, and stress are all contributors. Expanding government and private sector actions, as well as firm programmes for the development of new medications to treat hypertension and diabetes, are likely to drive this area.
Hospital pharmacies, retail pharmacies, and other distribution channels make up the European nifedipine market. In 2020, hospital pharmacies dominated the market in the region, and it is expected to increase at a quicker CAGR over the forecast period.
By 2030, the Europe Nifedipine market is estimated to be worth USD 648.08 million, with a CAGR of 8.5% over the forecast period (2022–2030). The new WHO European Regional Obesity Report 2022, released on May 3 by the WHO Regional Office for Europe, shows that overweight and obesity rates have reached epidemic proportions across the Region and are still rising, with none of the Region's 53 Member States on track to meet the WHO Global Noncommunicable Disease (NCD) target of halting obesity rise by 2025, and as a result, more diseases are becoming prevalent, increasing demand for nifedipine in the resale market.
Obesity is low in France compared to other European countries, but it is on the rise, according to the most recent epidemiological census. In France, obesity has doubled in the last 25 years. A new national epidemiological study on overweight and obesity has been released. Obesity affects 17% of the French population, compared to 15% eight years earlier, accounting for almost 8,567,128 people. Numbers are rising and as a result many diseases are prevalent, which is driving up the use of Nifedipine in the region.
The proportion of the German population aged 65 and up is expected to reach 22% by 2020. This was a significant rise over the previous year, and the share has been steadily increasing year after year. This is a significant proportion of Germany's population ageing, which is likely to continue in the coming years, boosting the use of Nifedipine in the region as elderly people are likely to get affected with some or the other disease.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|